Novartis Korea, KFDA mulls voluntary withdrawal of Zelmac

Novartis Korea said on April 2 it discussed with the Korea Food and Drug Administration on the possibility of Zelmac (tegaserod) withdrawal from the market.

The U.S. Food and Drug Administration said on March 30 that Novartis had halted sales of tegaserod (Zelnorm), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, includin...